Regulation of mixed lineage kinase 3 is required for Neurofibromatosis-2- mediated growth suppression in human cancer

Oncogene

Volumn 30, Issue 7, 2011, Pages 781-789

  Zhan, Y ^a   Modi, N ^a   Stewart, A M ^a   Hieronimus, R I ^a   Liu, J ^b   Gutmann, D H ^c   Chadee, D N ^a  

^a UNIVERSITY OF TOLEDO   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

B Raf; Cdc42; MAPK; MLK3; NF2

Indexed keywords

B RAF KINASE; MERLIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 10; MIXED LINEAGE KINASE 3; PROTEIN CDC42; RHO GUANINE NUCLEOTIDE BINDING PROTEIN;

ARTICLE; CANCER INHIBITION; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; HUMAN CELL; NEUROFIBROMATOSIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; CDC42 GTP-BINDING PROTEIN; CELL LINE, TUMOR; CELL PROLIFERATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAP KINASE KINASE KINASES; MICE; NEOPLASMS; NEUROFIBROMIN 2; RATS; RHO GTP-BINDING PROTEINS;

EID: 79951810077     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.453     Document Type: Article

References (46)

1. Chadee DN, Kyriakis JM. (2004a). A novel role for mixed lineage kinase 3 (MLK3) in B-Raf activation and cell proliferation. Cell Cycle 3: 1227-1229. (Pubitemid 40268597)
2. Chadee DN, Kyriakis JM. (2004b). MLK3 is required for mitogen activation of B-Raf, ERK and cell proliferation. Nat Cell Biol 6: 770-776. (Pubitemid 39144483)
3. Chadee DN, Xu D, Hung G, Andalibi A, Lim DJ, Luo Z et al. (2006). Mixed-lineage kinase 3 regulates B-Raf through maintenance of the B-Raf/Raf-1 complex and inhibition by the NF2 tumor suppressor protein. Proc Natl Acad Sci USA 103: 4463-4468.
4. Chadee DN, Yuasa T, Kyriakis JM. (2002). Direct activation of mitogen-activated protein kinase kinase kinase MEKK1 by the Ste20p homologue GCK and the adapter protein TRAF2. Mol Cell Biol 22: 737-749. (Pubitemid 34053054)
5. Cho YY, Bode AM, Mizuno H, Choi BY, Choi HS, Dong Z. (2004). A novel role for mixed-lineage kinase-like mitogen-activated protein triple kinase alpha in neoplastic cell transformation and tumor development. Cancer Res 64: 3855-3864. (Pubitemid 38697296)
6. Du Y, Bock BC, Schachter KA, Chao M, Gallo KA. (2005). Cdc42 induces activation loop phosphorylation and membrane targeting of mixed lineage kinase 3. J Biol Chem 280: 42984-42993. (Pubitemid 43049262)
7. Fernandez-Valle C, Tang Y, Ricard J, Rodenas-Ruano A, Taylor A, Hackler E et al. (2002). Paxillin binds schwannomin and regulates its density-dependent localization and effect on cell morphology. Nat Genet 31: 354-362. (Pubitemid 35154443)
8. Fraenzer JT, Pan H, Minimo Jr L, Smith GM, Knauer D, Hung G. (2003). Overexpression of the NF2 gene inhibits schwannoma cell proliferation through promoting PDGFR degradation. Int J Oncol 23: 1493-1500.
9. Gallo KA, Johnson GL. (2002). Mixed-lineage kinase control of JNK and p38 MAPK pathways. Nat Rev Mol Cell Biol 3: 663-672. (Pubitemid 34987787)
10. Gollob JA, Wilhelm S, Carter C, Kelley SL. (2006). Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol 33: 392-406. (Pubitemid 44142735)
11. Gonzalez-Agosti C, Wiederhold T, Herndon ME, Gusella J, Ramesh V. (1999). Interdomain interaction of merlin isoforms and its influence on intermolecular binding to NHE-RF. J Biol Chem 274: 34438-34442. (Pubitemid 129511790)
12. Goutebroze L, Brault E, Muchardt C, Camonis J, Thomas G. (2000). Cloning and characterization of SCHIP-1, a novel protein interacting specifically with spliced isoforms and naturally occurring mutant NF2 proteins. Mol Cell Biol 20: 1699-1712. (Pubitemid 30100189)
13. Gutmann DH, Haipek CA, Burke SP, Sun CX, Scoles DR, Pulst SM. (2001). The NF2 interactor, hepatocyte growth factor-regulated tyrosine kinase substrate (HRS), associates with merlin in the 'open' conformation and suppresses cell growth and motility. Hum Mol Genet 10: 825-834.
14. Hartkamp J, Troppmair J, Rapp UR. (1999). The JNK/SAPK activator mixed lineage kinase 3 (MLK3) transforms NIH 3T3 cells in a MEK-dependent fashion. Cancer Res 59: 2195-2202. (Pubitemid 29217685)
15. Hung G, Li X, Faudoa R, Xeu Z, Kluwe L, Rhim JS et al. (2002). Establishment and characterization of a schwannoma cell line from a patient with neurofibromatosis 2. Int J Oncol 20: 475-482.
16. Ikeda K, Saeki Y, Gonzalez-Agosti C, Ramesh V, Chiocca EA. (1999). Inhibition of NF2-negative and NF2-positive primary human meningioma cell proliferation by overexpression of merlin due to vector-mediated gene transfer. J Neurosurg 91: 85-92.
17. Jannatipour M, Dion P, Khan S, Jindal H, Fan X, Laganiere J et al. (2001). Schwannomin isoform-1 interacts with syntenin via PDZ domains. J Biol Chem 276: 33093-33100.
18. Jin H, Sperka T, Herrlich P, Morrison H. (2006). Tumorigenic transformation by CPI-17 through inhibition of a merlin phosphatase. Nature 442: 576-579. (Pubitemid 44167917)
19. Khatlani TS, Wislez M, Sun M, Srinivas H, Iwanaga K, Ma L et al. (2007). c-Jun N-terminal kinase is activated in non-small-cell lung cancer and promotes neoplastic transformation in human bronchial epithelial cells. Oncogene 26: 2658-2666. (Pubitemid 46632007)
20. Kissil JL, Wilker EW, Johnson KC, Eckman MS, Yaffe MB, Jacks T. (2003). Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1. Mol Cell 12: 841-849. (Pubitemid 37352778)
21. Kyriakis JM, Avruch J. (2001). Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 81: 807-869. (Pubitemid 32267078)
22. Lee JY, Moon HJ, Lee WK, Chun HJ, Han CW, Jeon YW et al. (2006). Merlin facilitates ubiquitination and degradation of transactivation-responsive RNA-binding protein. Oncogene 25: 1143-1152.
23. Leung IW, Lassam N. (2001). The kinase activation loop is the key to mixed lineage kinase-3 activation via both autophosphorylation and hematopoietic progenitor kinase 1 phosphorylation. J Biol Chem 276: 1961-1967. (Pubitemid 32109674)
24. Liu J, Yang G, Thompson-Lanza JA, Glassman A, Hayes K, Patterson A et al. (2004). A genetically defined model for human ovarian cancer. Cancer Res 64: 1655-1663. (Pubitemid 38428686)
25. Lutchman M, Rouleau GA. (1995). The neurofibromatosis type 2 gene product, schwannomin, suppresses growth of NIH 3T3 cells. Cancer Res 55: 2270-2274.
26. McClatchey AI, Saotome I, Ramesh V, Gusella JF, Jacks T. (1997). The Nf2 tumor suppressor gene product is essential for extraembryonic development immediately prior to gastrulation. Genes Dev 11: 1253-1265. (Pubitemid 27235358)
27. Morrison H, Sherman LS, Legg J, Banine F, Isacke C, Haipek CA et al. (2001). The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev 15: 968-980. (Pubitemid 32323547)
28. Morrison H, Sperka T, Manent J, Giovannini M, Ponta H, Herrlich P. (2007). Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac. Cancer Res 67: 520-527. (Pubitemid 46192188)
29. Obremski VJ, Hall AM, Fernandez-Valle C. (1998). Merlin, the neurofibromatosis type 2 gene product, and beta1 integrin associate in isolated and differentiating Schwann cells. J Neurobiol 37: 487-501. (Pubitemid 28549213)
30. Okada T, Lopez-Lago M, Giancotti FG. (2005). Merlin/NF-2 mediates contact inhibition of growth by suppressing recruitment of Rac to the plasma membrane. J Cell Biol 171: 361-371. (Pubitemid 41540027)
31. Poulikakos PI, Xiao GH, Gallagher R, Jablonski S, Jhanwar SC, Testa JR. (2006). Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK. Oncogene 25: 5960-5968. (Pubitemid 44477290)
32. Ramesh V. (2004). Merlin and the ERM proteins in Schwann cells, neurons and growth cones. Nat Rev Neurosci 5: 462-470.
33. Rana A, Gallo K, Godowski P, Hirai S, Ohno S, Zon L et al. (1996). The mixed lineage kinase SPRK phosphorylates and activates the stress-activated protein kinase activator, SEK-1. J Biol Chem 271: 19025-19028. (Pubitemid 26271557)
34. Reed N, Gutmann DH. (2001). Tumorigenesis in neurofibromatosis: new insights and potential therapies. Trends Mol Med 7: 157-162. (Pubitemid 32280374)
35. Rennefahrt U, Illert B, Greiner A, Rapp UR, Troppmair J. (2004). Tumor induction by activated JNK occurs through deregulation of cellular growth. Cancer Lett 215: 113-124. (Pubitemid 39221466)
36. Rennefahrt UE, Illert B, Kerkhoff E, Troppmair J, Rapp UR. (2002). Constitutive JNK activation in NIH 3T3 fibroblasts induces a partially transformed phenotype. J Biol Chem 277: 29510-29518. (Pubitemid 41079238)
37. Rong R, Surace EI, Haipek CA, Gutmann DH, Ye K. (2004). Serine 518 phosphorylation modulates merlin intramolecular association and binding to critical effectors important for NF2 growth suppression. Oncogene 23: 8447-8454. (Pubitemid 39540795)
38. Scoles DR, Huynh DP, Chen MS, Burke SP, Gutmann DH, Pulst SM. (2000). The neurofibromatosis 2 tumor suppressor protein interacts with hepatocyte growth factor-regulated tyrosine kinase substrate. Hum Mol Genet 9: 1567-1574. (Pubitemid 30426993)
39. Shaw RJ, Paez JG, Curto M, Yaktine A, Pruitt WM, Saotome I et al. (2001). The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. Dev Cell 1: 63-72. (Pubitemid 33586069)
40. Sherman L, Xu HM, Geist RT, Saporito-Irwin S, Howells N, Ponta H et al. (1997). Interdomain binding mediates tumor growth suppression by the NF2 gene product. Oncogene 15: 2505-2509.
41. Sun CX, Robb VA, Gutmann DH. (2002). Protein 4.1 tumor suppressors: getting a FERM grip on growth regulation. J Cell Sci 115: 3991-4000. (Pubitemid 35446798)
42. Teramoto H, Coso OA, Miyata H, Igishi T, Miki T, Gutkind JS. (1996). Signaling from the small GTP-binding proteins Rac1 and Cdc42 to the c-Jun N-terminal kinase/stress-activated protein kinase pathway. A role for mixed lineage kinase 3/protein-tyrosine kinase 1, a novel member of the mixed lineage kinase family. J Biol Chem 271: 27225-27228. (Pubitemid 26367270)
43. Vacratsis PO, Gallo KA. (2000). Zipper-mediated oligomerization of the mixed lineage kinase SPRK/MLK-3 is not required for its activation by the GTPase cdc 42 but Is necessary for its activation of the JNK pathway. Monomeric SPRK L410P does not catalyze the activating phosphorylation of Thr258 of murine MITOGEN-ACTIVATED protein kinase kinase 4. J Biol Chem 275: 27893-27900.
44. Velho S, Oliveira C, Paredes J, Sousa S, Leite M, Matos P et al. (2010). Mixed lineage kinase 3 gene mutations in mismatch repair deficient gastrointestinal tumours. Hum Mol Genet 19: 697-706.
45. Xiao GH, Gallagher R, Shetler J, Skele K, Altomare DA, Pestell RG et al. (2005). The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression. Mol Cell Biol 25: 2384-2394. (Pubitemid 40354632)
46. Zhang H, Gallo KA. (2001). Autoinhibition of mixed lineage kinase 3 through its Src homology 3 domain. J Biol Chem 276: 45598-45603.